z-logo
Premium
An orthotopic endometrial cancer mouse model demonstrates a role for RUNX1 in distant metastasis
Author(s) -
Doll Andreas,
Gonzalez Marta,
Abal Miguel,
Llaurado Marta,
Rigau Marina,
Colas Eva,
Monge Marta,
Xercavins Jordi,
Capella Gabriel,
Diaz Berta,
GilMoreno Antonio,
Alameda Francesc,
Reventos Jaume
Publication year - 2009
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.24330
Subject(s) - endometrial cancer , metastasis , cancer research , medicine , cancer , carcinoma , oncology , malignancy , carcinogenesis , pathology , biology
Endometrial carcinoma is the most common malignancy of the female genital tract in industrialized countries. Metastasis is the major cause of endometrial cancer deaths. Therefore, there is a vital need for clinically relevant in vivo models allowing the elucidation of the molecular and cellular mechanisms underlying metastatic behavior. In this study, we describe an innovative experimental orthotopic model of human endometrial carcinoma. Implantation in the bifurcation of the uterine horns resulted in tumors integrated into the myometrial compartment, which can be used and further exploited for the study of in vivo angiogenesis, myometrial invasion, and the metastatic capacity of endometrial cancer cells. This orthotopic model also represents a suitable tool to analyze how tumorigenesis and distant metastasis of endometrial cancer might be influenced by gene alteration, by modulating its expression in the original cancer cell line. One of the candidate genes implicated in endometrial cancer is the transcription factor RUNX1. The over‐expression of RUNX1 in the endometrial cancer cell line HEC1A and the transplantation of these cells to the uterus of nude mice were associated specifically with distant metastasis in the lung. RUNX1 plays a role in the establishment of metastases in endometrial cancer. Translated to the clinics, these models would be equivalent to an advanced undifferentiated carcinoma with node affectation (stage IIIC) and distant metastasis (stage IVB). These patients would be candidates for adjuvant therapy, not efficient until today, and therefore, our models are actually suitable for the design and evaluation of experimental therapies. © 2009 UICC

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here